An observational study in Chronic Kidney Diseases, Cardio-Renal Syndrome and Myocardial Fibrosis, sponsored by Dr Manvir Kaur Hayer. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.
Sponsored by Dr Manvir Kaur Hayer · Observational
This study aims to understand the onset an functional consequences of left ventricular interstitial fibrosis in patients with chronic kidney disease (stage 2 to 5), as well as assess whether transplantation results in a regression of cardiac fibrosis.Thus all patients will undergo: 1) a cardiac magnetic resonance imaging (MRI) scan to assess cardiac function and measure left ventricular interstitial fibrosis; 2) a cardiopulmonary stress echocardiogram to understand the functional consequences of fibrosis and rule out any underlying ischaemic heart disease; 3) a 24 hour holter monitor and electrocardiogram (ECG) to assess whether these patients are at higher risk of arrhythmia.
Aim and objectives:
The primary objective of this study is to test the following hypotheses:
i) Patients with early stage chronic kidney disease (CKD) exhibit diffuse LV fibrosis manifest by prolonged native myocardial T1 times and expansion of the extracellular volume (ECV) measured on MRI with a graded relationship to eGFR (stage of CKD), independent of blood pressure and arterial stiffness.
The secondary research objectives are to test the following hypotheses:
i) Prolonged native myocardial T1 times are associated with impaired diastolic function, altered arterial-ventricular interaction and impaired effort tolerance.
ii) Prolonged T1 times correlate with increases in serum biomarkers of collagen turnover associated with myocardial fibrosis that could be used to risk stratify individuals and enable targeted, personalized clinical care.
iii) Renal transplantation results in a regression of myocardial fibrosis as measured by T1 mapping.
DESIGN:
A cross-sectional analysis of 40 patients in each stage 2-5 CKD will be undertaken. These individuals will only be studied once (at baseline). In addition to this, at least 20 patients will be studied who are about to undergo a kidney transplant. These individuals will be studied at baseline (around the time of surgery), at 6 weeks post-operatively, and then 1 year post-operatively to assess the effect on renal transplantation on myocardial fibrosis.
SUBJECTS:
Patients will be recruited from the clinics run by University Hospitals Birmingham NHS Foundation Trust (UHB) with stages 2, 3, 4 and 5 CKD defined using eGFR calculated with the 4-variable 'Modification of Diet in Renal Disease' (MDRD) equation, with a minimum of two consecutive tests at least 90 days apart. Forty patients will be recruited per group of CKD. All study subjects will undergo a cardiac MRI scan, a cardiopulmonary exercise tests with stress echocardiogram, a 24-hour ECG holter monitor, and blood tests.
CONTROLS:
Forty healthy control subjects and forty hypertensive control subjects will be studied. All patients will undergo the identical research protocol to the CKD subjects, except they will not have a stress echocardiogram or an ECG holter monitor.
3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.
This study's planned enrollment of 260 is above the median of 192 across 1,033 observational studies indexed under Kidney Diseases.
Browse Kidney Diseases studies →This is the only study on the registry with Dr Manvir Kaur Hayer as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Stable CKD from early to severe late stage (stage 2 to 5). Patients expected to undergo live-donor kidney transplantation. Healthy controls. Hypertensive controls (stable, well controlled hypertension).
Exclusion Criteria:
40 patients per group of CKD from stage 2 to stage 5.
Diagnostic Test: cardiac magnetic resonance scan · Diagnostic Test: Cardiopulmonary exercise test with stress echocardiogram · Diagnostic Test: 24-hour ECG holter monitor · Diagnostic Test: 12-lead ECG · Biological: Blood test
20 live-donor recipients will be studied pre-operatively and then followed up at 6 weeks and 1 years post-operatively.
Diagnostic Test: cardiac magnetic resonance scan · Diagnostic Test: 24-hour ECG holter monitor · Diagnostic Test: 12-lead ECG · Diagnostic Test: Cardiopulmonary exercise test · Biological: Blood test
40 healthy controls and 40 hypertensive controls.
Diagnostic Test: cardiac magnetic resonance scan · Diagnostic Test: Cardiopulmonary exercise test with stress echocardiogram · Diagnostic Test: 12-lead ECG · Diagnostic Test: Cardiopulmonary exercise test · Biological: Blood test
An MRI scan of the heart
An exercise bicycle test with echocardiogram done during the exercise.
3 stickers attached to a small monitor are worn for 24 hours.
Can be done immediately by the bedside.
An exercise bicycle test. No stress echocardiogram.
20 mls of blood will be taken to measure routine laboratory tests and biomarkers of fibrosis.
The effect of eGFR on heart muscle scarring (measured from cardiac MRI using T1 times).
eGFR is a measurement of kidney function. Heart muscle scarring levels can be derived from cardiac MRI using a technique called T1 mapping. T1 maps of the heart will be acquired using cardiac MRI. eGFR will be measured from a blood tests, using the MDRD equation. The relationship between the measured T1 times and eGFR will be analysed using statistical tests.
Time frame: One baseline visit only
The relationship between prolonged myocardial T1 and diastolic function.
The following diastolic function parameters will be measured on echocardiography: E/A, deceleration time and E/e'.
Time frame: One baseline visit only
The relationship between prolonged myocardial T1 and effort tolerance.
The percent predicted peak oxygen uptake during exercise testing will be used as a surrogate marker of effort tolerance.
Time frame: One baseline visit only
The effect of renal transplantation on myocardial fibrosis.
Myocardial T1 times (cardiac MRI) and eGFR (blood testing) will best measured.
Time frame: Baseline visit (pre-operation), then follow up at 6 weeks and 1 year.
Plan to share: Undecided
This study is status unknown, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.